2[2]Eadie MJ.Therapeutic drug monitoring antiepileptic drugs.Br J Clin Pharmacol,1998,46(2):185-193
3[3]Petroff OAC,Rothman DL,Behar KL,et al.The effect of gabapentin on brain gammaaminobutyric acid in patients with epilepsy.Ann Neurol,1996,39 (1):95 -99
4[4]Wilson EA,Sills GJ,Forrest G,et al.High dose gabapentin in refractory partial epilepsy:clinical observations in 50 patients.Epilepsy Res,1998,29(4):539-542
5[5]May TW,Rambeck B,Jurgens U.Serum concentrations of lamotrigine in epileptic patients:The influence of dose and comedication.Ther Drug Monit,1996,18(4):523-531
6[6]Eriksson AS,Nergardh A,Hoppu K.The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy:A randomized double-blind,cross-over study.Epilepsy,1998,39 (4):495-501
7[7]Van Parys JAP,Meinardi H.Survey of 260 patients treated wot oxycarbazepine on a named-patient basis.Epilepsy Res,1994,19(1):79-85
8[8]Johannessen SI.Pharmacokinetics and interactions of topiramate.Epilepsy,1997,38[Suppl 1]:S18-S23
9[9]Perruca E,Bialer M.The clinical pharmacokinetics of the newer antiepileptic drugs.Focus on topiramate,zonisamide and tiagabine.Clin Pharmacokinet,1996,31 (1):29-46
10[10]Erdal J,Gram L,Alving J,et al.Changesin plasma GABA concentration during Vigabatrin treatment of epilepsy:A prospective study.Epilepsy Res,1999,34(2):145-150
